Trial of Cellceutix' topical defensin-mimetic compound for induction of remission of ulcerative proctitis and ulcerative proctosigmoiditis

Trial Profile

Trial of Cellceutix' topical defensin-mimetic compound for induction of remission of ulcerative proctitis and ulcerative proctosigmoiditis

Planning
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Defensin stimulants (Primary)
  • Indications Ulcerative proctitis; Ulcerative proctosigmoiditis
  • Focus Adverse reactions
  • Sponsors Innovation Pharmaceuticals
  • Most Recent Events

    • 29 Jan 2015 New trial record
    • 26 Jan 2015 Cellceutix is submitting a request to the US FDA for a pre-IND meeting, with the goal of initiating this trial in 2015, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top